Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00011037
Other study ID # HVTN 026/HIVNET 026
Secondary ID 10529HIVNET 026
Status Completed
Phase Phase 2
First received
Last updated
Est. completion date July 2004

Study information

Verified date October 2021
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test how the body's immune system responds to the vaccine ALVAC-HIV vCP1452 and to determine if the vaccine is safe when given alone and with MN rgp120. HIV infection and AIDS have no cure, in spite of recent advances in anti-HIV drugs. Many worldwide populations cannot afford the antiviral treatments for infected people. HIV vaccines offer hope for disease prevention. In this trial, 2 experimental HIV vaccines called ALVAC vCP1452 and MN rgp120 will be given to volunteers in Haiti, Brazil, Peru, and Trinidad and Tobago. The study will determine how volunteers' immune systems respond to the vaccines. (This protocol has been changed by adding new international sites.)


Description:

There is no cure for HIV infection or AIDS in spite of recent advances in antiviral therapy. Furthermore, drug therapy is too expensive for most affected populations. For this reason, there is a commitment to the development of safe, effective vaccines to prevent HIV infection and AIDS worldwide. This study evaluates the immunogenicity and safety of candidate HIV-1 vaccines, based on the canarypox vector termed ALVAC, alone and combined with an MN rgp120 product, at 3 [AS PER AMENDMENT 7/19/01: 5] international sites. [AS PER AMENDMENT 7/19/01: Volunteers in Rio de Janeiro, Haiti, and Trinidad and Tobago comprise Part I; volunteers in Sao Paulo and Peru comprise Part II.] Volunteers from Haiti, Brazil, [AS PER AMENDMENT 7/19/01: Peru] and Trinidad and Tobago are enrolled into 1 of 3 arms and followed for 18 months. Arm 1 volunteers receive ALVAC-HIV vCP1452 at 0, 1, 3, and 6 months. Arm 2 volunteers receive ALVAC-HIV vCP1452 on the same schedule as Arm 1 and receive HIV-1 MN rgp120 subunit simultaneously with the 3-month and 6-month vaccine doses. Arm 3 volunteers receive a placebo. Blood and urine samples are collected for immunologic assays, virologic determinations, pregnancy testing, and safety assessments. Risk behavior and social harms are assessed every 6 months during follow-up [AS PER AMENDMENT 7/19/01: Social harms are assessed every 3 months during follow-up and risk behavior every 6 months]. At all clinic visits volunteers receive counseling on avoidance of HIV infection and pregnancy. Participants are tested for HIV-1 every 3 [AS PER AMENDMENT 7/19/01: the following text has been deleted: to 6] months. Counseling and follow-up for any needed medical care are provided.


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date July 2004
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria Volunteers may be eligible for this study if they: - Are from Brazil (Rio de Janeiro), Haiti, Peru, or Trinidad and Tobago. - Are 18 to 60 years old. - Are HIV-negative. - Have not developed a sexually transmitted disease in the last 6 months. - Have had no more than 2 sexual partners in the last 6 months. - Have not injected drugs or used crack cocaine in the last 6 months. - Have not exchanged sex for money or drugs in the last 6 months. - Have used an adequate birth control method for 1 month prior to study injections and intend to continue for the injection period (7 months). - Are available for 18 months of follow-up. - Have a normal history and physical examination. - (The criteria for inclusion have been changed from the original.) Exclusion Criteria Volunteers will not be eligible for this study if they: - Have had immune diseases, chronic illness, or cancer (unless cured by surgical removal), or have used medications affecting the immune system. - Have a medical or mental condition, or job that interferes with the study requirements. - Have a sexual partner who is HIV-infected, unless practicing abstinence or have always used condoms for the last 6 months. - Have a sexual partner at high risk of HIV infection. - Have received live vaccines or experimental agents within 30 days prior to planned vaccination. - Have received blood products or immunoglobulin in the past 6 months. - Have active tuberculosis. - Have had a severe allergic reaction, including 1 requiring hospitalization or medical care, or a serious reaction to vaccines. - Have received HIV-1 vaccines or placebo in a previous HIV vaccine trial. - Are pregnant or breast-feeding. - Are allergic to egg products, thimerosal, or neomycin.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
ALVAC(2)120(B,MN)GNP (vCP1452)
1 x 10^ 7 TCID50 administered intramuscularly
MN rgp120/HIV-1
0.6 mg administered intramuscularly
ALVAC(2)120(B,MN)GNP (vCP1452) placebo
ALVAC placebo administered intramuscularly
MN rgp120/HIV-1 placebo
Alum placebo administered intramuscularly

Locations

Country Name City State
Brazil Projeto Praça Onze/Hesfa Crs Rio de Janeiro
Haiti Les Centres GHESKIO CRS Port-au-Prince
Peru Barranco CRS Lima
Trinidad and Tobago CCPRI Med. Ctr. - Med. Research Foundation of Trinidad & Tobago Port of Spain

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Countries where clinical trial is conducted

Brazil,  Haiti,  Peru,  Trinidad and Tobago, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immunogenicity and safety of two vaccine regimens Throughout study
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2